HALO

Business Context and Reporting Period

Company: Halozyme Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Halozyme is a biopharmaceutical company developing products targeting the extracellular matrix, primarily utilizing its proprietary recombinant human PH20 enzyme (rHuPH20). The company operates through two marketed products (HYLENEX and Cumulase) and strategic partnerships with Roche and Baxter to apply its Enhanze Technology to biological therapeutics. The company has incurred net operating losses since inception.

Key Financial Metrics

Revenue Composition (2008): Revenues under collaboration agreements totaled approximately $8.05 million, while product sales were $0.71 million. Collaboration revenue is primarily derived from the amortization of upfront license fees and reimbursements for R&D services from Baxter and Roche.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 131% year-over-year, driven by a 155% increase in collaboration revenues ($8.05M vs $3.16M). This was due to higher amortization of license fees and increased R&D reimbursements from partners.
• Expense Surge: Operating expenses increased 85% to $59.20 million. Research and Development (R&D) expenses more than doubled to $44.23 million (up 115%), primarily due to increased outsourced R&D costs ($10.6M increase), higher compensation ($6.6M increase), and expanded clinical trials. Selling, General, and Administrative (SG&A) expenses rose 30% to $14.63 million.
• Cash Position: Cash and cash equivalents decreased by $33.96 million to $63.72 million. Net cash used in operating activities was $35.37 million, compared to $0.15 million used in 2007. This reflects the significant increase in operating losses and reduced cash receipts from partnership payments.
• Stock Price Volatility: The common stock traded between a high of $8.26 and a low of $2.60 during 2008.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Management anticipates a net cash burn of approximately $30.0 million to $35.0 million for the year ending December 31, 2009.
• Current cash resources are expected to fund operations for at least the next twelve months.
• The company expects to raise additional capital in the future through public offerings, private financings, or expanded collaborations to fund continued development.

Key Developments:

• Roche Partnership: Roche elected to add a fourth exclusive target to the collaboration in December 2008. Phase I trials for two targets have commenced.
• Baxter Partnership: A Phase III clinical trial for GAMMAGARD LIQUID with rHuPH20 commenced in January 2009. Baxter prepaid an additional $5.5 million in product-based payments in January 2009.
• Product Pipeline: Phase II trials for Insulin-PH20 (diabetes) began in November 2008. Phase I trials for PEGPH20 (oncology) and Bisphosphonate-PH20 (osteoporosis) were initiated in 2008. The Chemophase program (bladder cancer) was deprioritized in Q1 2009 to focus resources on higher priority programs.

Risks and Contingencies:

• Profitability: The company has never been profitable and expects to incur significant operating losses for the foreseeable future.
• Liquidity: Future funding requirements depend on clinical progress and regulatory approvals. Failure to secure additional financing could force delays or elimination of R&D programs.
• Manufacturing: The company relies entirely on third-party contract manufacturers (Avid Bioservices and Cook Pharmica) for its active pharmaceutical ingredient. Scaling up production for the Roche partnership is critical.
• Regulatory: Future revenues depend on obtaining FDA approval for product candidates, which is uncertain and costly.

Investor Verification Checklist

• Cash Runway: Verify if the projected $30M-$35M cash burn for 2009 aligns with current cash balances ($63.7M) and anticipated milestone receipts.
• Deferred Revenue Recognition: Review the terms of the Roche and Baxter agreements to understand the timeline for recognizing the $49.45 million in deferred revenue.
• Manufacturing Capacity: Confirm the status of the technology transfer and scale-up at the second manufacturer (Cook Pharmica) required for the Roche partnership.
• Clinical Milestones: Monitor the results of the Phase II Insulin-PH20 trial (results expected mid-2009) and the Phase III GAMMAGARD LIQUID trial, as these are critical for future milestone payments.
• Dilution Risk: Note the existence of approximately 1.9 million outstanding warrants and the potential for future equity issuances under the $50 million shelf registration.